Recent findings from the IMPAACT P1115 study confirm the safety and therapeutic drug concentrations of a nevirapine-based antiretroviral regimen in the early neonatal period. The study's aim was to establish dosing of nevirapine for very early treatment of HIV-exposed neonates at high risk of HIV acquisition.
Citation: Ruel TD et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2020 Nov 23;S2352-3018(20)30274-5.
Original Article (subscription may be required)